Tu Youyou

1930–1968: pharmacy and the institutional joining of medical traditions

Tu was born in Ningbo, Zhejiang, on 30 December 1930. From 1951 to 1955 she studied pharmacognosy—the identification and study of medicinal substances from natural sources—in the pharmacy department of Peking University Medical School, which became the independent Beijing Medical College during her course. On graduation she was assigned to the Institute of Chinese Materia Medica in the newly established Academy of Traditional Chinese Medicine under the Ministry of Health.

Her education belonged to a particular programme of the early People's Republic, not to a timeless blending of “East” and “West.” Between 1959 and 1962, the Ministry of Health placed Tu in full-time training in Chinese medical theory, clinical practice, and the processing of materia medica. In her Nobel autobiography, Tu presents that training as essential to her later reading of preparations as technical procedures. Because the account was written after her award, it is evidence of her formation and later self-understanding, not an independent record of every remembered detail.

1967–1969: war, chloroquine resistance, and Project 523

China convened Project 523 on 23 May 1967—hence its numerical code—after North Vietnam requested help with malaria during the Vietnam War. Malaria was also a serious disease in southern China, while chloroquine-resistant Plasmodium falciparum had made the military problem more urgent. The programme distributed synthetic-chemical screening, traditional-remedy surveys, clinical work, and drug production across civilian and military institutions. Miller and Su's reconstruction estimates more than 500 researchers in about sixty laboratories, figures best understood as the scale of the programme rather than a fixed roster.

This mobilisation occurred during the Cultural Revolution (1966–1976), when universities and ordinary publication were severely disrupted and many intellectuals were persecuted. Project 523's strategic importance protected selected work and resources, while military secrecy limited normal scientific publication. In January 1969 Tu was appointed to lead the Institute of Chinese Materia Medica's contribution to the herbal search. She did not direct the whole national project, as some abbreviated biographies imply.

1969–1971: field collection, texts, failed extracts, and no. 191

Tu and colleagues consulted written formularies, gathered local knowledge, and visited malaria-affected areas including Hainan. Their survey converted heterogeneous indications such as fevers and “intermittent fevers” into leads for tests against experimental malaria parasites. This translation was not straightforward: a historical fever category was not necessarily malaria, plant names could refer to more than one species, and an old preparation was not a standardized dose.

After early qinghao preparations lost activity, the Ge Hong passage helped Tu reconsider heat, plant parts, and solvents. The successful neutral ether fraction, extract no. 191, was obtained on 4 October 1971 according to Project 523 documents reproduced and interpreted by Su and Miller. Animal findings supplied a promising lead, not yet a medicine: toxicity, identity, dose, formulation, recurrence, and clinical performance still had to be investigated.

1972–1979: early treatment, crystals, structure, and collective publication

In her 2015 Nobel lecture, Tu recalled that she and colleagues took the extract themselves before an August 1972 investigation in twenty-one malaria patients on Hainan, followed by nine patients in Beijing. A 2025 history of controlled trials in China classifies these investigations as uncontrolled but promising. They were conducted under emergency and political pressure, not designed or reported to current randomisation, consent, and oversight standards. The surviving accounts show rapid fever and parasite clearance, but they do not provide enough patient-level evidence to support the later shorthand that Tu personally “cured malaria.”

Purification then proceeded in several places. Tu's retrospective account says her group isolated an active crystal in November 1972; Miller and Su's 2011 account stresses that Yunnan and Shandong teams soon obtained high-quality crystals after Tu's March report. Those positions are compatible about Tu's catalytic role but differ in how they narrate isolation priority. Researchers at the Institute of Chinese Materia Medica, Shanghai Institute of Organic Chemistry, Institute of Biophysics of the Chinese Academy of Sciences, and other units jointly established the unusual peroxide-containing structure in the mid-1970s.

Secrecy and collective conventions shaped the publication record. A short Chinese report appeared under a collaborative group name in 1977. The first broad English-language report, “Antimalaria Studies on Qinghaosu”, appeared in the Chinese Medical Journal in December 1979 with no individual authors listed. It reported chemistry, animal work, and accumulated clinical experience under a coordinating-group identity. It is indispensable primary evidence for what the collaboration made public, but it does not allocate individual credit or preserve patients' perspectives.

1981–2015: a slow international route and late individual recognition

Tu presented the work to a visiting World Health Organization group in Beijing in 1981, but global adoption was not immediate. Questions about formulations, manufacturing quality, safety, institutional trust, and which derivatives to develop slowed international programmes. Trials in Southeast Asia during the late 1980s and 1990s confirmed rapid parasite clearance; larger trials later established artesunate's advantage over quinine in severe malaria. Because artemisinin compounds leave the body quickly, combination with a longer-acting partner drug proved more effective and helps protect against resistance.

A clinical history by White, Hien, and Nosten traces the disputed international development and WHO's clear 2006 recommendation of artemisinin-based combination therapies (ACTs) as first-line treatment for uncomplicated falciparum malaria across endemic countries. Tu received the Lasker–DeBakey Clinical Medical Research Award in 2011 and half of the 2015 Nobel Prize in Physiology or Medicine “for her discoveries concerning a novel therapy against Malaria.” The award accurately recognised a crucial intervention; its individual form did not turn the whole Project 523 development chain into one person's work.

Qinghao (青蒿) is a historical drug name, while Artemisia annua is a botanical species and artemisinin is a purified chemical compound. Historian and anthropologist Elisabeth Hsu has shown that Chinese texts and practitioners distinguished plants imperfectly translated into a single modern identity: both A. annua and A. apiacea supplied material called qinghao, with classifications and preferred uses changing over time.

Ge Hong's fourth-century instruction concerned an “intermittent fever” within the medical language of his own period. Retrospective identification of every such fever with parasitologically confirmed malaria would erase diagnostic uncertainty. Nor does the passage validate raw wormwood as a modern treatment: plant chemistry varies, dosing is uncertain, and a crude preparation is not equivalent to a quality-controlled ACT. The historically defensible claim is that an old preparation instruction helped a twentieth-century team formulate a testable extraction hypothesis.

The strongest case for Tu rests on a sequence: her institute's group revived the qinghao lead, made the active low-temperature neutral extract, reported it to the national network in March 1972, led early human investigation, and continued with purification and dihydroartemisinin. Su and Miller argue from Project 523 meeting summaries, later interviews, and records supplied by Tu that these were the initiating contributions on which later work depended.

The strongest collective account points to how the programme itself worked. Information circulated internally; Yunnan and Shandong groups produced crystals; Guangzhou researchers undertook major clinical studies; Beijing and Shanghai institutes solved the structure; other teams developed derivatives, combinations, and manufacture. The 1979 national award went to institutions, and early papers often used group authorship. “Tu alone discovered artemisinin” is therefore too broad, while “Tu was merely one of hundreds” obscures the documented experimental redirection her team supplied.

The archive itself explains some disagreement. Military secrecy delayed publication, Cultural Revolution conventions discouraged individual authorship, and much detailed chronology became public only in retrospective accounts made when prizes and priority were at stake. Exact claims about who first obtained a crystal depend on how “first,” “pure,” and “artemisinin” are defined and which internal records receive greatest weight. This page therefore identifies the secure sequence and retains the attribution dispute rather than pretending the surviving evidence is uniform.

Artemisinin compounds rapidly reduce malaria parasites in the blood, but they do not prevent mosquito transmission by themselves or remove the environmental, political, and health-system conditions that sustain malaria. Their global impact depended on diagnosis, affordable manufacture, procurement, clinical guidance, trained staff, and combination with other treatment and prevention measures. It is more accurate to say that artemisinin transformed malaria treatment than that Tu “cured malaria.”

In current practice, the World Health Organization recommends ACTs—not unstandardized Artemisia preparations or oral artemisinin alone—for uncomplicated P. falciparum malaria and chloroquine-resistant P. vivax. WHO defines artemisinin partial resistance as delayed parasite clearance; it has been confirmed in the Greater Mekong subregion and several African countries. ACTs usually remain effective where the partner drug works. This contemporary note explains why combination therapy belongs to the historical legacy, not how an individual reader should diagnose or treat malaria.